Lumenis

Company Overview

Snapshot

Founded in December 1991 by Dr. Shimon Eckhouse, Lumenis operates with over 1,000 employees. The company has secured $77.51M across 4 funding rounds. In February 2020, Lumenis was acquired by Baring Private Equity Asia.

Business overview

Lumenis specializes in providing minimally invasive clinical solutions for the surgical, ophthalmologic, and aesthetic markets. The company develops and commercializes energy-based technologies, including laser, intense pulsed light, and radio frequency. Lumenis focuses on creating solutions for previously untreatable conditions and enhancing existing treatment methods across the sectors it serves, operating within the Health Tech & Life Sciences sector.

Strategic signal

Lumenis continues to innovate in the aesthetic medical device market, as evidenced by the launch of its new Stellar M22 Skin Treatments Platform with XPL Technology in November 2025. This introduction, backed by new clinical data, signals the company's ongoing commitment to advancing energy-based aesthetic solutions and expanding its product portfolio, reinforcing its position in the competitive medical technology landscape.

Company Intelligence Q&A

When was Lumenis acquired?

Lumenis was acquired by Baring Private Equity Asia in February 2020.

What was a significant product launch by Lumenis in 2025?

In November 2025, Lumenis launched its new Stellar M22 Skin Treatments Platform with.

What new technology did Lumenis introduce in March 2026?

In March 2026, Lumenis unveiled triLIFT 2.0, introducing advancements in dynamic muscle stimulation for face and body treatments.

What award did Lumenis' triLift receive in May 2024?

In May 2024, Lumenis' triLift was awarded "Best New Dermatology Technology Solution" in the 8th Annual MedTech Breakthrough Awards Program.

What new hair loss treatment did Lumenis introduce in June 2024?

In June 2024, Lumenis introduced FoLix, the first FDA-cleared proprietary fractional laser for hair loss treatment.